Skip to main content

Infections, Human Immunodeficiency Virus and Herpesviridae

7
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
7
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
5 programs
5
Dolutegravir 50 mg tabletPhase 1
GSK1265744 injectable suspensionPhase 1
GSK1349572Phase 1
GSK1349572Phase 1
GSK2248761 WBM CapsulePhase 1
Shionogi
ShionogiJapan - Osaka
2 programs
2
Dolutegravir 50 mg tabletPhase 1
GSK1349572Phase 1
GSK
GSKLONDON, United Kingdom
4 programs
Dolutegravir 50 mg tabletPHASE_11 trial
GSK1349572PHASE_11 trial
GSK1349572PHASE_11 trial
GSK2248761 WBM CapsulePHASE_11 trial
Active Trials
NCT01382238Completed20Est. Aug 2011
NCT01209065Completed27Est. Nov 2010
NCT01098526Completed12Est. May 2010
+1 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GSKDolutegravir 50 mg tablet
GSKGSK1349572
GSKGSK2248761 WBM Capsule
GSKGSK1349572

Clinical Trials (4)

Total enrollment: 83 patients across 4 trials

NCT01382238GSKDolutegravir 50 mg tablet

Relative Bioavailability Study of a Pediatric Granule Formulation of Dolutegravir

Start: Jun 2011Est. completion: Aug 201120 patients
Phase 1Completed
NCT01209065GSKGSK1349572

GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir

Start: Sep 2010Est. completion: Nov 201027 patients
Phase 1Completed
NCT01209117GSKGSK2248761 WBM Capsule

A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435

Start: Sep 2010Est. completion: Jan 201124 patients
Phase 1Completed
NCT01098526GSKGSK1349572

GSK1349572 Drug Interaction Study With Efavirenz

Start: Mar 2010Est. completion: May 201012 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.